Monthly
US$200
Billed every month
Doxycycline Hyclate Tablets(盐酸多西环素片)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 1 application
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders5View records ↓
Under-review filings10View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers56View records ↓
API companies with A status12View records ↓
Chemical-drug catalogue
Loaded records: 5 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 2 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 广州市陌希生物技术有限公司 | 广州康和药业有限公司 | 国药准字H20269241 | 2026/09/29 | 50mg（按C22H24N2O8计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 广州市陌希生物技术有限公司 | 广州康和药业有限公司 | 国药准字H44022831 | 2026/09/29 | 100mg（按C22H24N2O8计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 德全药品（江苏）股份有限公司 | 德全药品（江苏）股份有限公司 | 国药准字H20266127 | 2026/09/29 | 0.1g(按C22H24N2O8计) | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州呋欧医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20263331 | 2026/02/02 | 50mg（按C22H24N2O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州呋欧医药科技有限公司 | 浙江赛默制药有限公司 | 国药准字H20263332 | 2026/02/02 | 0.1g（按C22H24N2O8计） | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 特一药业集团股份有限公司 | 特一药业集团股份有限公司 | 国药准字H44021106 | 2025/02/25 | 0.1g（按C22H24N2O8计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 特一药业集团股份有限公司 | 特一药业集团股份有限公司 | 国药准字H44023645 | 2025/02/25 | 0.05g（按C22H24N2O8计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 江苏联环药业股份有限公司 | 江苏联环药业股份有限公司 | 国药准字H32021266 | 2022/03/30 | 0.1g(按C22H24N2O8计） | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 56 distinct approval numbers and 43 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 广东邦民制药厂有限公司 | 国药准字H44022263 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010100267 | NHSA |
| 广东彼迪药业有限公司 | 国药准字H44021610 | 按C22H24N2O8计0.1g | Category A (甲) | XJ01AAD193A001010100269 | NHSA |
| 广东华南药业集团有限公司 | 国药准字H44025005 | 按C22H24N2O8计算0.1g | Category A (甲) | XJ01AAD193A001010100290 | NHSA |
| 广东南国药业有限公司 | 国药准字H44021882 | 按C22H24N208计0.05g | Category A (甲) | XJ01AAD193A001010100315 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010100341 | NHSA |
| 广东众生药业股份有限公司 | 国药准字H44021455 | 0.1g(以C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010100353 | NHSA |
| 广州白云山光华制药股份有限公司 | 国药准字H44020175 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010100372 | NHSA |
| 广州康和药业有限公司 | 国药准字H44022831 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010100401 | NHSA |
| 丽珠集团利民制药厂 | 国药准字H44020593 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010100454 | NHSA |
| 上海上药信谊药厂有限公司 | 国药准字H31021129 | 0.1g(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010100818 | NHSA |
| 辉瑞制药有限公司 | 国药准字H19993983 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010101187 | NHSA |
| 江苏涟水制药有限公司 | 国药准字H32023940 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010101466 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H32021266 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010101467 | NHSA |
| 江苏平光制药有限责任公司 | 国药准字H32021227 | 0.1g( 按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010101471 | NHSA |
| 江苏瑞年前进制药有限公司 | 国药准字H32020684 | 按C22H24N208计算0.1g | Category A (甲) | XJ01AAD193A001010101474 | NHSA |
| 苏州弘森药业股份有限公司 | 国药准字H32020364 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010101518 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20266127 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010101751 | NHSA |
| 宜昌人福药业有限责任公司 | 国药准字H42022002 | 0.1g | Category A (甲) | XJ01AAD193A001010102000 | NHSA |
| 成都第一制药有限公司 | 国药准字H51022998 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010102080 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064734 | 0.1g | Category A (甲) | XJ01AAD193A001010102439 | NHSA |
| 西安迪赛生物药业有限责任公司 | 国药准字H61020895 | 0.1g | Category A (甲) | XJ01AAD193A001010102470 | NHSA |
| 河北长天药业有限公司 | 国药准字H13020640 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010102596 | NHSA |
| 河北东风药业有限公司 | 国药准字H13021945 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010102605 | NHSA |
| 万邦德制药集团有限公司 | 国药准字H13022241 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010102779 | NHSA |
| 大同市利群药业有限责任公司 | 国药准字H14020498 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010102844 | NHSA |
| 安阳市华安药业有限责任公司 | 国药准字H41020833 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010102996 | NHSA |
| 上海安丁生物(汤阴)药业有限公司 | 国药准字H41021433 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010103062 | NHSA |
| 天方药业有限公司 | 国药准字H41020347 | 按C22H24N2O8计 0.1g | Category A (甲) | XJ01AAD193A001010103098 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010103139 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H41022128 | 0.1g(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010103182 | NHSA |
| 河南大新药业有限公司 | 国药准字H41021958 | 按C22H24N2O8计算0.1g | Category A (甲) | XJ01AAD193A001010103225 | NHSA |
| 开封康诺药业有限公司 | 国药准字H41023619 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010103244 | NHSA |
| 吉林万通药业集团梅河药业股份有限公司 | 国药准字H22023683 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010103498 | NHSA |
| 哈尔滨泰华药业股份有限公司 | 国药准字H19994039 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010103673 | NHSA |
| 烟台鲁银药业有限公司 | 国药准字H37022402 | 按C22H24N2O8计算0.1g | Category A (甲) | XJ01AAD193A001010104240 | NHSA |
| 安徽长江药业有限公司 | 国药准字H34021049 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010104451 | NHSA |
| 福建省三明天泰制药有限公司 | 国药准字H35020048 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010104805 | NHSA |
| 江西青峰药业有限公司 | 国药准字H20143033 | 20mg(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010105337 | NHSA |
| 江西新赣江药业股份有限公司 | 国药准字H36020566 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010105375 | NHSA |
| 海南赛立克药业有限公司 | 国药准字H46020437 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010105805 | NHSA |
| 甘肃兰药药业有限公司 | 国药准字H62020641 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010105863 | NHSA |
| 甘肃成纪生物药业有限公司 | 国药准字H62020111 | 0.1g | Category A (甲) | XJ01AAD193A001010105889 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H41022128 | 0.1g(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010158310 | NHSA |
| 杭州呋欧医药科技有限公司 | 国药准字H20263331 | 按C₂₂H₂₄N₂O₈计 50mg | Category A (甲) | XJ01AAD193A001010184160 | NHSA |
| 广东南国药业有限公司 | 国药准字H44021882 | 按C22H24N208计0.05g | Category A (甲) | XJ01AAD193A001010200315 | NHSA |
| 广东众生药业股份有限公司 | 国药准字H44021455 | 0.1g(以C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010200353 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20266127 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010201751 | NHSA |
| 河北东风药业有限公司 | 国药准字H13021945 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010202605 | NHSA |
| 大同市利群药业有限责任公司 | 国药准字H14020498 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010202844 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010203139 | NHSA |
| 濮阳市汇元药业有限公司 | 国药准字H41022128 | 0.1g(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001010203182 | NHSA |
| 河南大新药业有限公司 | 国药准字H41021958 | 按C22H24N2O8计算0.1g | Category A (甲) | XJ01AAD193A001010203225 | NHSA |
| 烟台鲁银药业有限公司 | 国药准字H37022403 | 按C22H24N2O8计算50mg | Category A (甲) | XJ01AAD193A001010204240 | NHSA |
| 福建省三明天泰制药有限公司 | 国药准字H35020048 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010204805 | NHSA |
| 甘肃成纪生物药业有限公司 | 国药准字H62020111 | 0.1g | Category A (甲) | XJ01AAD193A001010205889 | NHSA |
| 杭州呋欧医药科技有限公司 | 国药准字H20263331 | 按C₂₂H₂₄N₂O₈计 50mg | Category A (甲) | XJ01AAD193A001010284160 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20266127 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010301751 | NHSA |
| 河北东风药业有限公司 | 国药准字H13021945 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010302605 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41022186 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010303139 | NHSA |
| 河南大新药业有限公司 | 国药准字H41021958 | 按C22H24N2O8计算0.1g | Category A (甲) | XJ01AAD193A001010303225 | NHSA |
| 德全药品(江苏)股份有限公司 | 国药准字H20266127 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001010401751 | NHSA |
| 河北东风药业有限公司 | 国药准字H13021945 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010402605 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41022186 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010403139 | NHSA |
| 河北东风药业有限公司 | 国药准字H13021945 | 0.1g(按C22H24N208计) | Category A (甲) | XJ01AAD193A001010502605 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010503139 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010603139 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001010703139 | NHSA |
| 广东华南药业集团有限公司 | 国药准字H44025004 | 按C22H24N2O8计算0.05g | Category A (甲) | XJ01AAD193A001020100290 | NHSA |
| 广东南国药业有限公司 | 国药准字H44021881 | 按C22H24N208计0.1g | Category A (甲) | XJ01AAD193A001020100315 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001020100341 | NHSA |
| 广州白云山光华制药股份有限公司 | 国药准字H44020431 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020100372 | NHSA |
| 广州康和药业有限公司 | 国药准字H44022831 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020100401 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H32021266 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001020101467 | NHSA |
| 成都第一制药有限公司 | 国药准字H51022999 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020102080 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064733 | 50mg | Category A (甲) | XJ01AAD193A001020102439 | NHSA |
| 天方药业有限公司 | 国药准字H41020868 | 按C22H24N2O8计 0.05g | Category A (甲) | XJ01AAD193A001020103098 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020947 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020103139 | NHSA |
| 河南大新药业有限公司 | 国药准字H41021959 | 按C22H24N2O8计算0.05g | Category A (甲) | XJ01AAD193A001020103225 | NHSA |
| 江西青峰药业有限公司 | 国药准字H20143033 | 20mg(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001020105337 | NHSA |
| 江西新赣江药业股份有限公司 | 国药准字H36020567 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020105375 | NHSA |
| 杭州呋欧医药科技有限公司 | 国药准字H20263332 | 按C₂₂H₂₄N₂O₈计 0.1g | Category A (甲) | XJ01AAD193A001020184160 | NHSA |
| 广东南国药业有限公司 | 国药准字H44021881 | 按C22H24N208计0.1g | Category A (甲) | XJ01AAD193A001020200315 | NHSA |
| 广州康和药业有限公司 | 国药准字H44022831 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020200401 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H32021266 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001020201467 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020947 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001020203139 | NHSA |
| 江西青峰药业有限公司 | 国药准字H20143033 | 20mg(按C22H24N2O8计算) | Category A (甲) | XJ01AAD193A001020205337 | NHSA |
| 杭州呋欧医药科技有限公司 | 国药准字H20263332 | 按C₂₂H₂₄N₂O₈计 0.1g | Category A (甲) | XJ01AAD193A001020284160 | NHSA |
| 广东南国药业有限公司 | 国药准字H44021881 | 按C22H24N208计0.1g | Category A (甲) | XJ01AAD193A001030100315 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030100341 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H32021266 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030101467 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064734 | 0.1g | Category A (甲) | XJ01AAD193A001030102439 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001030103139 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030200341 | NHSA |
| 江苏联环药业股份有限公司 | 国药准字H32021266 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030201467 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064734 | 0.1g | Category A (甲) | XJ01AAD193A001030202439 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020946 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001030203139 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030300341 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064734 | 0.1g | Category A (甲) | XJ01AAD193A001030302439 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41022186 | 0.1g(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001030303139 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030400341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030500341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030600341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44023645 | 0.05g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001030700341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040100341 | NHSA |
| 陕西西岳制药有限公司 | 国药准字H20064734 | 0.1g | Category A (甲) | XJ01AAD193A001040102439 | NHSA |
| 开封制药(集团)有限公司 | 国药准字H41020947 | 50mg(按C22H24N2O8计) | Category A (甲) | XJ01AAD193A001040103139 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040200341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040300341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040400341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040500341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040600341 | NHSA |
| 特一药业集团股份有限公司 | 国药准字H44021106 | 0.1g(按C₂₂H₂₄N₂O₈计) | Category A (甲) | XJ01AAD193A001040700341 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 10 filings and 8 distinct first applicants.
Generic 8 · Supplement 2
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏润恒制药有限公司 | CYHS2502969 | Generic | 2025/08/14 | Not stated by source | CDE |
| 江苏润恒制药有限公司 | CYHS2502968 | Generic | 2025/08/14 | Not stated by source | CDE |
| 福建海西新药创制股份有限公司 | CYHS2601459 | Generic | 2026/06/22 | Not stated by source | CDE |
| 安徽杰玺医药有限公司 | CYHS2601168 | Generic | 2026/05/18 | Not stated by source | CDE |
| 安徽杰玺医药有限公司 | CYHS2601167 | Generic | 2026/05/18 | Not stated by source | CDE |
| 河北东风药业有限公司 | CYHB2650110 | Supplement | 2026/04/30 | Not stated by source | CDE |
| 浙江益汉制药有限公司 | CYHS2504388 | Generic | 2025/12/25 | Not stated by source | CDE |
| 华中药业股份有限公司 | CYHS2503937 | Generic | 2025/11/13 | Not stated by source | CDE |
| 成都硕德药业有限公司 | CYHS2503512 | Generic | 2025/09/25 | Not stated by source | CDE |
| 江西科睿药业有限公司;江西青峰药业有限公司 | CYHB2602003 | Supplement | 2026/11/04 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 3 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 福建海西新药创制股份有限公司 | CYHS2601459 | Generic | 2026/06/22 | Not stated by source | CDE |
| 安徽杰玺医药有限公司 | CYHS2601168 | Generic | 2026/05/18 | Not stated by source | CDE |
| 安徽杰玺医药有限公司 | CYHS2601167 | Generic | 2026/05/18 | Not stated by source | CDE |
API registrations
Non-component matches: 12 companies with A status and 1 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 盐酸多西环素 | 南通常佑药业科技有限公司 | Y20240001089 | A | Exact ingredient | 2026/08/15 | CDE |
| 多西环素 | 南通常佑药业科技有限公司 | Y20240000584 | I | Salt-normalized ingredient | 2024/08/21 | CDE |
| 盐酸多西环素 | HOVIONE PHARMASCIENCE LIMITED | Y20220000451 | A | Exact ingredient | 2026/05/20 | CDE |
| 盐酸多西环素 | 上海青平药业有限公司 | Y20190006582 | A | Exact ingredient | 2026/01/31 | CDE |
| 盐酸多西环素 | 昆山东方药业有限公司 | Y20190006560 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 | 石家庄华曙善合药业有限公司 | Y20190006021 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 | 河北东风药业有限公司 | Y20190005098 | A | Exact ingredient | 2025/02/09 | CDE |
| 盐酸多西环素 | 苏州第五制药厂有限公司 | Y20190005068 | A | Exact ingredient | — | CDE |
| 盐酸多西环素 | 盐城苏海制药有限公司 | Y20190004892 | A | Exact ingredient | 2025/07/18 | CDE |
| 盐酸多西环素 | 常州制药厂有限公司 | Y20190004505 | A | Exact ingredient | 2025/07/09 | CDE |
| 盐酸多西环素 | 江苏联环药业股份有限公司 | Y20190004072 | A | Exact ingredient | 2025/07/30 | CDE |
| 盐酸多西环素 | 开封制药（集团）有限公司 | Y20190002589 | A | Exact ingredient | 2024/09/11 | CDE |
| 盐酸多西环素 | 山东鲁抗医药股份有限公司 | Y20190002114 | A | Exact ingredient | 2025/01/23 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/11/04Accepted
江西科睿药业有限公司;江西青峰药业有限公司
CYHB2602003
Fact date: 2026/11/04 · Site observation date: 2026/11/05
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Doxycycline Hyclate Tablets
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy